Spruce Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.435
- Today's High:
- $2.75
- Open Price:
- $2.44
- 52W Low:
- $0.955
- 52W High:
- $3.57
- Prev. Close:
- $2.28
- Volume:
- 912725
Company Statistics
- Market Cap.:
- $90.78 million
- Book Value:
- 2.372
- Revenue TTM:
- $4.13 million
- Operating Margin TTM:
- -1231.24%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.57%
- Return on Equity TTM:
- -51.87%
Company Profile
Spruce Biosciences Inc had its IPO on 2020-10-09 under the ticker symbol SPRB.
The company operates in the Healthcare sector and Biotechnology industry. Spruce Biosciences Inc has a staff strength of 32 employees.
Stock update
Shares of Spruce Biosciences Inc opened at $2.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.44 - $2.75, and closed at $2.54.
This is a +11.4% increase from the previous day's closing price.
A total volume of 912,725 shares were traded at the close of the day’s session.
In the last one week, shares of Spruce Biosciences Inc have increased by +13.9%.
Spruce Biosciences Inc's Key Ratios
Spruce Biosciences Inc has a market cap of $90.78 million, indicating a price to book ratio of 0.3152 and a price to sales ratio of 0.
In the last 12-months Spruce Biosciences Inc’s revenue was $4.13 million with a gross profit of $0 and an EBITDA of $-50754000. The EBITDA ratio measures Spruce Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Spruce Biosciences Inc’s operating margin was -1231.24% while its return on assets stood at -27.57% with a return of equity of -51.87%.
In Q2, Spruce Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Spruce Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Spruce Biosciences Inc’s profitability.
Spruce Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3564. Its price to sales ratio in the trailing 12-months stood at 0.
Spruce Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $125.96 million
- Total Liabilities
- $22.73 million
- Operating Cash Flow
- $22.00 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Spruce Biosciences Inc ended 2024 with $125.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $125.96 million while shareholder equity stood at $96.56 million.
Spruce Biosciences Inc ended 2024 with $2.81 million in deferred long-term liabilities, $22.73 million in other current liabilities, 4000.00 in common stock, $-174928000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $97.48 million and cash and short-term investments were $120.52 million. The company’s total short-term debt was $1,622,000 while long-term debt stood at $2.51 million.
Spruce Biosciences Inc’s total current assets stands at $124.13 million while long-term investments were $0 and short-term investments were $23.04 million. Its net receivables were $0 compared to accounts payable of $945000.00 and inventory worth $0.
In 2024, Spruce Biosciences Inc's operating cash flow was $22.00 million while its capital expenditure stood at $0.
Comparatively, Spruce Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.54
- 52-Week High
- $3.57
- 52-Week Low
- $0.955
- Analyst Target Price
- $7.5
Spruce Biosciences Inc stock is currently trading at $2.54 per share. It touched a 52-week high of $3.57 and a 52-week low of $3.57. Analysts tracking the stock have a 12-month average target price of $7.5.
Its 50-day moving average was $2.21 and 200-day moving average was $2.15 The short ratio stood at 0.5 indicating a short percent outstanding of 0%.
Around 44.1% of the company’s stock are held by insiders while 9176% are held by institutions.
Frequently Asked Questions About Spruce Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.